Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Improperly Filed Quest Alliance With Nasdaq, Failed to Obtain Investor Approval

NEW YORK, Jan. 16 (GenomeWeb News) - Ciphergen Biosystems has received a deficiency notification from the Nasdaq National Market indicating that the company failed to comply with the continued listing requirements of the exchange, the company said late last week.

 

According Ciphergen, the Nasdaq said the company did not file a listing notification and obtain shareholder approval for its July 22, 2005, stock sale to Quest Diagnostics. As GenomeWeb News reported at the time, a part of an R&D alliance between the two companies called for Ciphergen to sell Quest around 6.2 million shares of stock along with a warrant to purchase 2.2 million additional shares. The combined sale would give Quest a 17-percent stake in Ciphergen.

 

Ciphergen said the Nasdaq indicated that it believes the Quest deal "constituted a change of control which required shareholder approval because the number of shares purchased by Quest, together with the number of shares potentially issuable upon exercise of the warrant, could exceed 20 percent of the total number of outstanding shares of common stock" of Ciphergen.

 

Ciphergen said that the arrangement provides that Quest will not own more than 19.9 percent of Ciphergen.

 

Ciphergen said it has until Jan. 17 to present its opinion on the matter to Nasdaq.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more